RVTYRevvity

Health care · Lab Instruments · NYSE

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. 10-K, Item 1

Employees: 11,000
Headquarters: Waltham, MA
CEO: Prahlad R. Singh
Next results: around Jan 12, 2027

Compare with peers → Embed

Key numbers

Latest fiscal year, with ten years behind each

RevenueFY2016–25 $2.9B+3.7% FY2024: $2.8B 10-K FY2025 · XBRL Net incomeFY2016–25 $241.2M−10.8% FY2024: $270.4M 10-K FY2025 · XBRL Free cash flowFY2016–25 $509.4M−6.0% FY2024: $541.7M 10-K FY2025 · XBRL Operating marginFY2016–25 12.5%−0.1 pts 13.9% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 24, 2026 against Feb 25, 2025

Area	What changed	Source
Risk factors	4 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Receivables growing faster than revenue	Receivables +17.8% vs revenue +3.7% (+14.1 pts)	10-K · XBRL
Accounting checks	10 other checks clear, 1 worth a look	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	1 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 24, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-25. Quoted as filed.

Uncertainties related to the development, deployment and use of AI to advance our product offerings and improve internal operations may result in harm to our business and reputation. We are advancing AI across our product and service offerings, and we are in the initial phases of expanding AI into the core functions of our business. The…
10-K, Item 1A

All 4 new paragraphs →

Accounting checks

latest 10-K

10 of 11 clear 1 worth a look. Checks, not verdicts.

!
Receivables growing faster than revenueReceivables +17.8% vs revenue +3.7% (+14.1 pts)
✓
Cash from operations $582.9M vs net income $241.2M (FY ending 2025-12-28)
✓
Inventory +3.2% vs revenue +3.7% (-0.4 pts)
✓
Same auditor in both 10-Ks: DELOITTE & TOUCHE LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
The same matters as last year: Goodwill - Life Sciences Solutions Reporting Unit; Boston, Massachusetts; February 24, 2026
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 3, 20268-K Quarterly results, Other events 8-K items 2.02, 8.01

About Revvity

10-K, Feb 24, 2026

We are a leading provider of health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. Our headquarters are in Waltham, Massachusetts, and we market our products and services in more than 160 countries. As of December 28, 2025, we employed approximately 11,000 employees.

Headquarters: Waltham, MA
Country: United States
Reports in: USD
Listed on: NYSE
Fiscal year ends: December 29
Last results: Nov 3, 2026
Incorporated in: MA

Employees, at the top of the page: "As of December 28, 2025, we employed approximately 11,000 employees" (10-K). Address and exchange: SEC's company file.

Permanent link, kept if the ticker changes: /c/sec:0000031791 (SEC's CIK).

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on RVTY in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/RVTY/export.csv") into a cell.